FOLH1 and neoplasm: After two treatment cycles, the 3.70 GBq cohort (n = 3) demonstrated 100% PSA reduction (3/3), with 66.7% (2/3) achieving ≥50% PSA decline; simultaneously, Response Evaluation Criteria in PSMA PET/CT (RECIP) 1.0 assessment showed partial response (PR) in 66.7% (2/3) of patients and stable disease (SD) in 33.3% (1/3).<h4>Conclusion</h4>[<sup>177</sup>Lu]Lu-LNC1011 was well tolerated across all dose levels, delivering high tumor-absorbed doses and prolonged tumor retention.